Indication:Graft versus host disease (GvHD) Acute and Chronic.
Myelofibrosis – Chronic idiopathic myelofibrosis and treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia
Rapid policy statement: Ruxolitinib for acute graft versus host disease
Rapid policy statement: Ruxolitinib for chronic Graft versus Host Disease
NICE TA 386